Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. by Inojosa, Walter O et al.
Inojosa, WO; Augusto, I; Bisoffi, Z; Josenado, T; Abel, PM; Stich,
A; Whitty, CJ (2006) Diagnosing human African trypanosomiasis in
Angola using a card agglutination test: observational study of active
and passive case finding strategies. BMJ (Clinical research ed), 332
(7556). p. 1479. ISSN 0959-8138 DOI: 10.1136/bmj.38859.531354.7C
Downloaded from: http://researchonline.lshtm.ac.uk/11536/
DOI: 10.1136/bmj.38859.531354.7C
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Research
Diagnosing human African trypanosomiasis in Angola using a card
agglutination test: observational study of active and passive case
finding strategies
Walter O Inojosa, Inacio Augusto, Zeno Bisoffi, Teofile Josenado, Paolo M Abel, August Stich, Christopher J M Whitty
Abstract
Objective To assess the operational feasibility of detecting
human African trypanosomiasis by active and passive case
finding using the card agglutination test with serial dilution of
serum to guide treatment.
Setting Trypanosomiasis control programme in the Negage
focus, northern Angola, during a period of civil war.
Design Observational study.
Participants 359 patients presenting themselves to health
centres with symptoms (passive case finding) and 14 446 people
actively screened in villages.
Main outcome measures Whole blood and serological tests at
different dilutions using the card agglutination test, and
detection of parasites by microscopy.
Results Active case finding identified 251 people with a positive
card agglutination test result, 10 of whom had confirmed
parasites. In those presenting for investigation 34 of 51 with a
positive card agglutination test result at the dilution of 1:8 or
more used to guide treatment had parasites in blood, lymph
node fluid, or cerebrospinal fluid, compared with 10 of 76 in
those detected by active case finding: positive predictive values
of 67% for passive case detection and 13% for active case
detection. Only at a cut-off dilution more than 1:32 was the
positive predictive value in active case detection reasonable
(46%) and at this dilution 40% of microscopically proved cases
were missed.
Conclusions The card agglutination test is useful for initial
screening in active detection of cases with human African
trypanosomiasis but, given the toxicity of the drugs, serology
using the card agglutination test should be not used alone to
guide treatment after active case finding. A second
confirmatory test is needed.
Introduction
Human African trypanosomiasis is one of the major parasitic
diseases of humans and is increasing in many parts of the conti-
nent.1 The disease, caused by protozoans transmitted by the
tsetse fly, has two forms, Trypanosoma brucei gambiense and T b
rhodesiense. T b gambiense causes most of the estimated
300 000-500 000 infections a year. The parasites are found in the
blood and lymphatic system but in more advanced disease
invade the brain. The disease is most common in areas of current
or recent civil breakdown; the Democratic Republic of Congo
has the greatest number of cases, followed by Angola with
around 100 000, but as only a fraction of the exposed population
is under adequate surveillance these are estimates. T b gambiense
causes sleeping sickness, the chronic, slowly progressive form of
human African trypanosomiasis, which is mostly fatal if left
untreated.
Early diagnosis and treatment of trypanosomiasis is essential,
as treatment of late stage disease is associated with high mortal-
ity. Humans are the reservoir of infection, so early treatment
helps to interrupt the parasite’s transmission cycle, providing an
efficient control strategy for active case finding campaigns.2 At
the same time over-diagnosis and consequent over-treatment are
potentially dangerous for patients. The most commonly used
drug for second stage treatment is melarsoprol, which contains
arsenic. The drug is highly toxic, with 2% to 10% mortality dur-
ing or shortly after treatment, mostly from arsenical reactive
encephalopathy.3 Attempts to modify the drug’s schedule have
not reduced mortality.4 A newer drug, eflornithine, is probably
safer than melarsoprol,5 but because of costs and difficulties of
administration it has not been adopted as first line treatment of
second stage disease in most sub-Saharan countries. First stage
treatment with pentamidine is less toxic but can cause severe side
effects, and up to 1% mortality has been reported during
treatment.6 Diagnostic systems therefore need to detect cases
early and minimise false positives to avoid exposing patients to
drugs that are dangerous or expensive, or both; a combination
that is difficult to achieve.
Even in high resource settings diagnosing trypanosomiasis is
not easy.7 Classically, diagnosis is based on direct visualisation of
parasites in the blood, lymph node fluid, or cerebrospinal fluid.8
Sensitivity of microscopy is often limited owing to low or fluctu-
ating parasitaemia. Examination of wet preparations of lymph
node fluid can detect 30%-70% of cases, and examination of
blood even by the most sensitive concentration technique of
mini-anion exchange centrifugation only adds another 5%-10%
of cases.9 Routine lumbar puncture is not recommended in
asymptomatic people with negative haemolymphatic examina-
tion results. Consequently at least 20% of infected people are lost
during active case finding and treatment surveys using
conventional methods of diagnosis.
The card agglutination test for trypanosomiasis, a method
developed for the detection of T b gambiense specific antibodies,10
is a simple tool for rapid screening of high patient numbers
under field conditions using whole blood. Sensitivity for T b gam-
biense varies between 87% and 98%, with an average of 95%,11
although this may vary by setting.12 The test is not sensitive for T
b rhodesiense. The test kits are cheap (around 30p) and screening
using the test is considered more cost effective then conventional
screening of lymph nodes.13 The World Health Organization rec-
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ommends follow-up every 3-6 months for people who have a
positive test result but no parasites on microscopic examination
of blood and lymph node fluid. This is difficult to maintain in
areas of complex emergency, however, where much of the
trypanosomiasis burden is found. Serial dilution of serum before
using the card agglutination test has been suggested as a
diagnostic confirmatory assay in those who have an initial posi-
tive result on screening to avoid the need for a prolonged and
potentially fatal wait.14 As with other serological tests, diluting
serum increases the specificity at the possible expense of
sensitivity; the higher the dilution at which a test remains positive
the more likely it is to be a true positive.
During the recent civil war in Angola few areas of the coun-
try could be reached easily and, as in many endemic areas where
trypanosomiasis is common, a screening approach requiring
only one visit was the only realistic way to identify cases and to
contain the infection reservoir using available resources.
Between 1999 and 2002 the control programme for trypano-
somiasis in Angola decided that all people who had a positive
serology result at a serum dilution of 1:8 or more with the card
agglutination test should be considered infected and therefore
treated regardless of evidence of parasites on microscopy.15
The empirical decision to treat a patient with no parasites
detected on microscopy on the basis of a high titre on the card
agglutination test has still to be fully evaluated under field condi-
tions. Although this decision aims at a major increase in
detection of true cases it could lead to over-diagnosis and subse-
quent treatment of false positives, which is expensive and poten-
tially hazardous. We determined whether titration using the card
agglutination test can be used to guide treatment in potential
cases of human African trypanosomiasis detected by passive and
active case finding.
Participants and methods
The study took place from February to May 2001 in the Negage
focus of the province of Uíge in northern Angola, where the
non-governmental organisation Caritas runs the human African
trypanosomiasis control programme, Angotrip.16 The study took
place during the final stage of the civil war. Patients with
symptoms presented themselves to the specialist treatment cen-
tre in Negage (passive case finding). Common symptoms were
headache, sleep disorder, arthralgia, itching, symptomatic
lymphadenopathy, behavioural change, and neurological prob-
lems (especially ataxia). Active case finding was by screening
people of all ages for trypanosomiasis in adjacent villages,
irrespective of symptoms, using village lists drawn up by munici-
pal authorities. All villagers were asked to attend screening at the
local school; 63% of those identified on the municipal lists
attended, although as these lists are often outdated the true pro-
portion of the population screened was probably much higher.
We consecutively registered all patients from both groups
and screened whole blood from each by the conventional card
agglutination test (Laboratory of Serology, Institute of Tropical
Medicine, Antwerp, Belgium). We considered asymptomatic
people with a negative test result free of the disease and they had
no further investigations. In accordance with the diagnostic pro-
tocol of the national control programme (figure),15 people with a
positive test result underwent cervical lymph node examination
for lymphadenopathy and, if present, subsequent examination of
a wet preparation of lymph node fluid. This examination was
carried out by conventional methods as recommended by
WHO.17 If trypanosomes were found the patient was treated.
Those without palpable lymph nodes or with a negative lymph
node fluid result had their blood examined for parasites by cap-
illary tube centrifugation (two tubes for each person)18; again the
patient was treated if trypanosomes were found. The cerebrospi-
nal fluid was double centrifuged and searched for trypano-
somes.19 We used the Fuchs-Rosenthal chamber to count white
blood cells in the cerebrospinal fluid.
For people with a positive card agglutination test result but
negative microscopic examination of blood and lymph node
fluid, we determined the serum end titre using the test. In addi-
tion, after obtaining informed consent, patients with confirmed
presence of parasites had a further blood sample taken to deter-
mine their serological status. For serum titration we centrifuged
5 ml of blood collected by venepuncture; we tested serum with
serial twofold dilution in card agglutination test buffer solution
and determined the highest dilution at which a sample remained
positive. Following the national guidelines at the time we consid-
ered people infected who were either positive for parasites or
positive using the card agglutination test result at a serum
dilution of 1:8 or more. They underwent a lumbar puncture for
differentiation of parasite stage, with cerebrospinal fluid
searched for trypanosomes and a white blood cell count carried
out. Finally, they were treated with pentamidine or melarsoprol
according to the parasite stage.
We entered laboratory and clinical data into Access
(Microsoft 97) and analysed the data using Stata version 8.
Evaluation of card agglutination test titres was carried out by
classic 2×2 tables. We assessed the sensitivity and positive predic-
tive value of serum titres at various cut-off dilutions. The gold
standard was microscopically proved cases. Microscopy is 100%
specific, although it has a recognised false negative rate. Absolute
sensitivities and specificities in the general population cannot be
calculated because for practical and ethical reasons the full para-
sitological investigation was not carried out on all those with a
negative card agglutination test result on whole blood, but we
report the relative sensitivities of higher dilutions.
Card agglutination test
on whole blood
Negative resultPositive result
Aspirate lymph
node if palpable
Negative result
on aspiration or 
non-palpable
lymph nodes
Capillary tube
centrifugation
of blood
Serial dilution of 
serum for card 
agglutination test
Dilution <1:8Dilution ≥1:8
positive
Not caseTreat as case
Positive
result
Negative result
Positive result
on aspiration
Flow of screening process
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Results
We consecutively screened 14 446 people of all age groups by
active case finding in the villages. In total 359 people with symp-
toms presented themselves to the treatment centre for examina-
tion and were consecutively registered in the study. They
constituted patients detected by passive case finding.
Active case finding in the villages led to the identification of
251 people with a positive card agglutination test result
(seroprevalence 1.7%). Seventy six people aged between 5 years
and 72 years (mean 33.2 years) had a positive reaction in serum
titration of 1:8 or more, but in only 10 (13%) people were para-
sites detected in either lymph node fluid or blood (table 1). Of
these just over half had symptoms, mostly non-specific: 43 had
headaches, 21 had itching, 10 had sleep disorders, 13 had
lymphadenopathy, and 4 had behavioural change or neurologi-
cal symptoms. Parasites were found only in people with card
agglutination test titres of 1:16 or more. No patients identified by
active case finding had detectable parasites in the cerebrospinal
fluid. The prevalence of parasitologically proved disease was low:
0.07% (10 of 14 446 people).
Eighty three people identified by passive case finding had a
positive card agglutination test result (seroprevalence 23.1%).
Fifty one people aged between 1 year and 56 years (mean 21.2
years) had elevated card agglutination test titres, of whom 34
(67%) had detectable parasites in lymph node fluid, blood, or
cerebrospinal fluid (table 2). Parasites were not found in people
with card agglutination test titres less than 1:8, and only one
patient with parasitologically proved disease had a titre equal to
1:8. Table 3 shows the distribution of parasites into blood, lymph
nodes, and cerebrospinal fluid. Haemolymphatic examination
detected 65% (22/34) of patients with parasitologically proved
disease. In 12 patients (35% of the total) trypanosomes were
found only in the cerebrospinal fluid; of these, six were either
asymptomatic or had non-specific symptoms not suggesting a
neurological diagnosis.
Table 4 shows the sensitivity and positive predictive values of
serology by active and passive case finding strategies. A positive
card agglutination test result on whole blood using active case
finding has a 4% positive predictive value with a ratio of false to
true positives of 24:1. When the cut-off titre is 1:8, the current
threshold to treat, the positive predictive value is 13.2%. The
effect of further serum dilution cut-off points are also shown in
table 4. At a cut-off dilution greater than 1:32 the positive
predictive value improves to 46%, but 40% of microscopically
proved cases are missed.
When using a passive case finding strategy with self referring
patients, the card agglutination test on whole blood has a 61.4%
positive predictive value. When the cut-off dilution is 1:8, the
positive predictive value is 66.7%. When the cut-off dilution is
1:32, the positive predictive value rises to 91.3%, but 38% of
parasitologically proved cases are missed.
Table 1 Evaluation of card agglutination test compared with parasite proved
disease after active case finding of people with human African
trypanosomiasis identified by mass screening
Cut-off dilution using
card agglutination test
Conventional parasitological methods*
TotalNo with positive
result
No with negative
result
Whole blood:
Positive result 10 241† 251
Negative result 0 14 195 14 195
Total 10 14 436 14 446
≥1:8:
Positive result 10 66† 76
Negative result 0 14 370 14 370
Total 10 14 436 14 446
≥1:16:
Positive result 10 39† 49
Negative result 0 14 397 14 397
Total 10 14 436 14 446
≥1:32:
Positive result 6 7† 13
Negative result 4 14 429 14 433
Total 10 14 436 14 446
*Capillary tube centrifugation, wet examination of lymph fluid, and examination of
cerebrospinal fluid.
†False positive result for serology.
Table 2 Evaluation of card agglutination test compared with parasite proved
disease using passive case detection where patients have presented with
symptoms of trypanosomiasis for diagnosis
Cut-off dilution using
card agglutination test
Conventional parasitological methods*
TotalNo with positive
result
No with negative
result
Whole blood:
Positive result 51 32† 83
Negative result 0 276 276
Total 51 308 359
≥1:8:
Positive result 34 17† 51
Negative result 0 308 308
Total 34 325 359
≥1:16:
Positive result 33 11† 44
Negative result 1 314 315
Total 34 325 359
≥1:32:
Positive result 21 2† 23
Negative result 13 323 336
Total 34 325 359
*Capillary tube centrifugation, wet examination of lymph fluid, and examination of
cerebrospinal fluid.
†False positive result for serology.
Table 3 Body fluids in which trypanosomes were found by passive case
detection
Body fluid No (%) of participants (n=34)
Lymph fluid 6 (18)
Lymph fluid and cerebrospinal fluid 5 (15)
Blood 8 (24)
Blood and cerebrospinal fluid 3 (9)
Cerebrospinal fluid 12 (35)
Table 4 Relative sensitivity and positive and negative predictive values of
card agglutination test compared with parasitologically proved
trypanosomiasis by active and passive case detection
Cut-off dilution using card
agglutination test Relative sensitivity (%)*
% positive predictive
value (95% CI)
Active case detection:
Whole blood — 4.0 (2 to 7)
≥1:8 100 (66 to 100) 13.2 (7 to 23)
≥1:16 100 (66 to 100) 20.4 (11 to 35)
≥1:32 60.1 (27 to 86) 46.2 (20 to 74)
Passive case detection:
Whole blood 100 (91 to 100) 61.4 (50 to 72)
≥1:8 100 (87 to 100) 66.7 (52 to 79)
≥1:16 97.1 (83 to 100) 75.0 (59 to 86)
≥1:32 61.8 (44 to 77) 91.3 (70 to 98)
*Starting population in active case finding of those screening positive on whole blood.
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Discussion
At the prevalence of human African trypanosomiasis found in
the general population ( < 1%) the positive predictive value of
the card agglutination test at the conventional serological cut-off
dilution of 1:8 is too low (13%) to guide treatment on its own.
Given the cost and significant toxicity of the drugs used in the
treatment of trypanosomiasis this is a serious problem; where
positive serological tests alone are used to guide treatment (as
had to be done in Angola at the time of our study) the overall
effect could even be harmful. In our setting the overall incidence
of reactive arsenical encephalopathy in those treated with melar-
soprol was 7.5%. The specificity of the card agglutination test is
considerably less than 100%, probably because other diseases
that induce false positive reactions (specifically in the area:
malaria, schistosomiasis, and filariasis) may cause symptoms
leading people to present themselves for diagnosis. For any test
even high specificities will correspond to low positive predictive
values when the prevalence of disease is low. According to our
data, when the prevalence of human African trypanosomiasis is
about 10%, only a cut-off dilution of 1:32 in passive surveillance
presents reasonable high positive predictive value (91%) to be a
sole guide to treatment with the available drugs, but at the cost of
missing a significant (and unacceptably high) number of true
cases.
Although microscopy is virtually 100% specific the card
agglutination test has a known rate of false positives, and this is
higher in endemic countries than when tested against blood
from people in non-endemic areas (often used to determine
specificities for tests). False positive low titre (1:5) card agglutina-
tion test results in people with schistosomiasis, filariasis, or toxo-
plasmosis have been reported.20 The presence of antimalarial
antibodies caused by recurrent malaria has been associated with
false positive results in the indirect fluorescent antibody test in
5% of cases.21 Both the indirect fluorescent antibody test and the
card agglutination test utilise freeze dried Trypanosoma brucei
gambiense LiTat 1.3 antigen. Tsetse flies are generally infected by
non-pathogenic trypanosomes at higher rates (often more than
10%) than by T b gambiense (invariably below 0.5%), and both
Trypanosoma congolense and Trypanosoma brucei brucei (non-
pathogenic) can lead to positive card agglutination test results in
infected animals. It can be hypothesised that non-pathogenic
trypanosomes might persist even in humans long enough to
induce a transiently positive card agglutination test result.
It is possible that newer and more specific serological tests
could improve on this, but even the best tests are not 100% spe-
cific under field conditions, which, given the dangers or expense
of treatment in human African trypanosomiasis, is a serious
problem in settings of low prevalence and poor resources.22 23
The results of our study suggest that for active case finding of
human African trypanosomiasis, serology is likely to be useful in
identifying those who need further testing with an unrelated test,
currently by conventional parasitological methods, but possibly
in the future by a second more specific serological test in much
the same way as blood is screened for HIV.
Carrying out research in complex emergency settings such as
civil war imposes limitations. The chance is that some, although
probably only a few, patients who have a positive card agglutina-
tion test result but whose disease is not parasitologically proved
would have gone on to have detectable parasites if repeatedly
sampled as recommended by WHO. The prevailing situation in
Angola at the time of the study did not make this a practical
option. Prospective follow-up studies of people with a positive
card agglutination test result but who are negative for parasites
with periodical parasitological examinations have given varying
results: in one study a 12 month follow-up of 71 people initially
only positive on the card agglutination test subsequently found
22 cases of infection,17 whereas in a 24 month follow-up of 77
people initially exclusively positive at serology subsequently
found only one case of infection.24
During the Angolan civil war many areas were hardly acces-
sible for health workers. The human African trypanosomiasis
control strategy had to be adapted to the reality that a single
examination of villagers might be their only chance to access
treatment against a fatal disease. Case finding is a key part of
control of trypanosomiasis. Even in stable situations long delays
occur in diagnosis, during which patients will deteriorate, possi-
bly irreversibly, while remaining a reservoir of infection.25 The
introduction of titration on the card agglutination test helped to
identify many infected patients and possibly to contain the
spread of the infection, but also subjected an unknown number
of people who were false positive to harmful treatments. Since
2002 Angola has been heading for political stability. Control
programmes can now undergo the transition from a humanitar-
ian crisis intervention programme to professional disease
containment and surveillance where individual case manage-
ment can again be given more consideration. Where resources
are severely constrained, as they are in most areas where human
African trypanosomiasis is a serious problem, using two tests
where one is adequate has to be avoided as it is costly.13 Our
study, however, suggests that the potential dangers of using labo-
ratory investigations that have even a reasonable specificity as the
sole guide for trypanosomiasis treatment where the prevalence is
low (all active case finding) are considerable in trypanosomiasis.
Although serology has a major part to play in active case identi-
fication, treatment should be based on a two stage screening
process where the first test is followed by another, independent
test in those found positive.
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What is already known on this topic
To prevent potentially fatal progression of human African
trypanosomiasis, and for control of the disease, cases must
be diagnosed early
Active case detection using the card agglutination test with
treatment given to those with a positive test at 1:8 dilution
has been advocated
What this study adds
Using the card agglutination test as the sole guide to
treatment of those identified by active case detection leads
to substantial over-diagnosis of the disease, with potentially
serious consequences
A two stage screening process with a sensitive test for active
case detection and a specific test for case confirmation is
the most appropriate strategy
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